Abstract:Background: Tryptophan metabolism via the kynurenine pathway is considered the link between the immune and endocrine systems. Dysregulation of serotonergic transmission can stem from the direct influence of interferon-α on the activity of serotonergic receptors 5-HT1A and 5-HT2A, and from its indirect effect on tryptophan metabolism. Induction of the kynurenine pathway increases the concentration of neurotoxic kynurenine metabolites, and the activity of kynurenine derivatives is linked to the onset of depression. The aim of our study was to evaluate the relationships between depressive symptoms and kynurenine, tryptophan, anthranilic acid and kynurenic acid concentrations, indolamine 2,3-dioxygenase (IDO) activity and tryptophan availability to the brain.Methods: The study followed a prospective longitudinal cohort design. We evaluated 101 patients with chronic hepatitis C who were treated with pegylated interferon-α2a, and 40 controls who were awaiting treatment. We evaluated the relationships between total score on the Montgomery-Åsberg Depression Rating Scale and kynurenine, tryptophan, anthranilic acid and kynurenic acid concentrations, IDO activity and tryptophan availability to the brain. A logistic regression model was adapted for the diagnosis of major depressive disorder at each time point, taking into account changes in parameters of the kynurenine pathway between a given time point and the baseline measurement.Results: Of the treated patients, 44% fulfilled the criteria for major depressive disorder at least once during the 24 weeks of treatment. Anthranilic acid concentrations were significantly increased compared to baseline for all time points except week 2. Tryptophan availability showed a significant decrease (β = -0.09, p = 0.01) only in week 12 of treatment. Over time, kynurenine, tryptophan and anthranilic acid concentrations, as well as IDO activity and tryptophan availability to the brain, were significantly associated with total score on the Montgomery-Åsberg Depression Rating Scale. A logistic regression model revealed that participants with decreased tryptophan availability to the brain at 12 weeks of treatment and participants with increased anthranilic acid concentrations at week 24 of treatment were at increased risk for diagnosis of major depressive disorder (odds ratios 2.92 and 3.59, respectively).Limitations: This study had an open-label design in a population receiving naturalistic treatment.Conclusion: The present study provides the first direct evidence of the role of anthranilic acid in the pathogenesis of inflammation-induced major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a.

IDO and interferon-|[alpha]|-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity

IDO and interferon- α -induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity

The Role of Indoleamine 2,3-Dioxygenase (IDO) in the Pathophysiology of Interferon-Alpha-induced Depression.

Increased Depressive Ratings in Patients with Hepatitis C Receiving Interferon-α–Based Immunotherapy Are Related to Interferon-α–Induced Changes in the Serotonergic System

Interferon-α-induced depressive symptoms are related to changes in the cytokine network but not to cortisol

Plasma Indoleamine-2,3-Dioxygenase (IDO) is Increased in Drug-Naï Ve Major Depressed Patients and Treatment with Sertraline and Ketoprofen Normalizes IDO in Association with Pro-Inflammatory and Immune- Regulatory Cytokines

The new ‘5-HT’ hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression

The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin

Selective Hyper-responsiveness of the Interferon System in Major Depressive Disorders and Depression Induced by Interferon Therapy

Psychological and Behavioural Effects of Interferons

Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation

Immunotherapy with Interferon-Alpha in Patients Affected by Chronic Hepatitis C Induces an Intercorrelated Stimulation of the Cytokine Network and an Increase in Depressive and Anxiety Symptoms

Interferon-gamma and Tumor Necrosis Factor-Alpha Mediate the Upregulation of Indoleamine 2,3-Dioxygenase and the Induction of Depressive-Like Behavior in Mice in Response to Bacillus Calmette-Guerin.

Treatment with Interferon-Alpha (ifnα) of Hepatitis C Patients Induces Lower Serum Dipeptidyl Peptidase IV Activity, Which is Related to IFNα-induced Depressive and Anxiety Symptoms and Immune Activation

HTR1A, TPH2, and 5-HTTLPR Polymorphisms and Their Impact on the Severity of Depressive Symptoms and on the Concentration of Tryptophan Catabolites during Hepatitis C Treatment with Pegylated Interferon-α2a and Oral Ribavirin (PEG-IFN-α2a/RBV)

Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes.

Interferon therapy and its association with depressive disorders - A review

Interferon-alpha-induced Modulation of Glucocorticoid and Serotonin Receptors As a Mechanism of Depression.

Depression Induced by Treatment with Interferon-Alpha in Patients Affected by Hepatitis C Virus.

Recent Advances of IDO Inhibitors

Discovery of 1-(Hetero)aryl-β-carboline Derivatives As IDO1/TDO Dual Inhibitors with Antidepressant Activity.